Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

2.1K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
2.1K
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

1.2K
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
1.2K
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics01:23

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

1.8K
Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla.  Benzonatate operates peripherally within the respiratory tract by...
1.8K
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

1.7K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.7K
Pneumonia IV: Management01:28

Pneumonia IV: Management

1.1K
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
1.1K
Drugs Used in Upper Respiratory Disorders: Overview01:16

Drugs Used in Upper Respiratory Disorders: Overview

1.0K
Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
1.0K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Implementing childhood obesity management in Ireland: stakeholder perspectives, priorities and recommendations for practice.

BMC health services research·2026
Same author

Community-based, supervised, group exercise for people living with chronic conditions and multimorbidity: a cohort study.

Age and ageing·2026
Same author

Prioritising and ranking methodological uncertainties in the design, conduct, and analysis of trials aiming to improve health outcomes for those living with multiple long-term conditions: A protocol for a modified Delphi study.

Journal of multimorbidity and comorbidity·2026
Same author

National and International Clinical Guidelines for the Management of Obesity in Adults: A Systematic Review.

Obesity reviews : an official journal of the International Association for the Study of Obesity·2026
Same author

AKT Signaling Differentially Regulates the Expression of Two Evolutionarily Conserved <i>Wnt5a</i> Isoforms in Lung Mesenchymal Cells.

Cells·2026
Same author

The Potential Role of Synovial T Cell Infiltration Following Knee Joint Injury in Symptoms and Progression to Osteoarthritis.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same journal

WHO Issues Guidelines for Treating Ebola and Marburg Viruses.

JAMA·2026
Same journal

FDA Approves Additional Naloxone Nasal Spray for Opioid Overdose.

JAMA·2026
Same journal

HIV May Hide in More Cells Than Previously Thought-Here's What That Could Mean for a Cure.

JAMA·2026
Same journal

US Dietary Supplement Use Increasing, Especially in Older Adults.

JAMA·2026
Same journal

Heat Stress From Climate Change Surges Globally.

JAMA·2026
Same journal

Strength Training Linked With Lower Cardiovascular Disease Risk in Women.

JAMA·2026
関連記事をすべて見る

関連する実験動画

Updated: Apr 19, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

15.4K

急性支障管炎に対する抗生物質

Susan M Smith1, John Smucny2, Tom Fahey1

  • 1HRB Centre for Primary Care Research, Department of General Practice, Royal College of Surgeons in Ireland Medical School, Dublin.

JAMA
|December 24, 2014
PubMed
まとめ
この要約は機械生成です。

急性支氣管炎に対する抗生物質は,咳の持続期間と疾患の重症度をわずかに減らすかもしれませんが,全体的に有意な臨床的改善はありません. 抗生物質を投与したグループは,特に消化器系の問題など,より多くの副作用を経験しました.

さらに関連する動画

P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives
10:26

P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives

Published on: June 15, 2020

12.0K
Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
15:43

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Published on: March 17, 2014

24.2K

関連する実験動画

Last Updated: Apr 19, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

15.4K
P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives
10:26

P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives

Published on: June 15, 2020

12.0K
Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
15:43

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Published on: March 17, 2014

24.2K

科学分野:

  • 一般的実践について
  • 感染症 感染症は感染症です.
  • 呼吸器医学とは

背景:

  • 急性支氣管炎は,一般的な呼吸器疾患であり,しばしば経験的に管理されます.
  • 急性支氣管炎の治療における抗生物質の役割は,臨床的な議論の対象であり続けています.

研究 の 目的:

  • 抗生物質の処方箋と,急性支氣管炎と診断された患者の臨床結果との関連性を評価する.

主な方法:

  • 抗生物質を投与された急性支柱炎患者とプラセボを投与された患者のアウトカムを評価する比較研究.

主要な成果:

  • 抗生物質の使用は,咳の持続時間,体調不良の日,活動障害のわずかな減少と関連していました.
  • 抗生物質とプラセボ群の間の全般的な臨床改善または機能的制限において有意な差異は観察されなかった.
  • 副作用,特に消化器系症状は,抗生物質群では著しく高かった.

結論:

  • 抗生物質は,急性支氣管炎の軽微な症状緩和を提供するかもしれないが,実質的な全体的な臨床的利益にはつながらない.
  • 急性支柱炎における抗生物質使用に関連した有害事象のリスクの増加は,慎重に検討する必要があります.